dose escalation, safety and pharmacokinetic study of ave8062 combined with docetaxel and cisplatin in patients with solid tumors

Conditions: Neoplasms, Malignant

Summary: primary objective: * to determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of ombrabulin in combination with docetaxel and cisplatin administered every 3 weeks in patients with advanced solid tumors secondary objectives: * to assess the overall safety profile of the combination therapy * to characterize the pharmacokinetic profile of ombrabulin, its active metabolite rpr 258063, docetaxel and cisplatin in combination. * to evaluate anti-tumor activity of the combination therapy

the duration of the study for each patient will include an up to 4-week screening phase, 21-day study treatment cycles, an end of treatment visit and a follow-up period 30 days after the last infusion of ombrabulin. the patient will continue treatment until disease progression, unacceptable toxicity, patient's refusal of further treatment.

Eligibility criteria:
inclusion criteria: * patients with advanced solid tumor for which docetaxel and cisplatin is approved such as lung cancer, epithelial ovarian cancer. exclusion criteria: * eastern cooperative oncology group performance status \> or = 2. * concurrent treatment with any other anticancer therapy. * male or female patients who do not agree with contraception. * washout period of less than 28 days from prior anticancer therapies (chemotherapy, targeted agents, immunotherapy and radiotherapy) or any investigational treatment, except for nitrosoureas, mitomycin which may not be used up to 42 days prior to the first cycle. no washout period is required for hormonal therapy that has to be discontinued before the first cycle. * not recovered from all previous therapies (radiation, surgery, and medications). adverse events related to previous therapies must be national cancer institute common terminology criteria (nci-ctcae v3.0) grade \< or = 1 (or alopecia \< or = grade 2) at screening or returned to the subject's baseline prior to their most recent previous therapy. * symptomatic brain metastases and carcinomatous leptomeningitis. * other serious illness or medical conditions not controlled by adequate treatment * patients with more than 1 line of previous chemotherapy for advanced or metastatic disease (adjuvant/neoadjuvant and targeted agents \[eg gefitinib\] excluded). * current peripheral neuropathy \> or = grade 2 and ototoxicity, of any origin including significant residual symptoms due to the use of neurotoxic drugs (eg vincaalkaloids, platinum and taxanes). * inadequate organ function * documented medical history of myocardial infarction, documented angina pectoris, arrhythmia especially severe conduction disorder such as second or third degree atrio-ventricular block, stroke, or history of arterial or venous thrombo-embolism within the past 180 days requiring anticoagulants. * patient with a left ventricular ejection fraction \<50% by echocardiography. * patients with a baseline qtc interval \>0.45, or family history of long qt syndrome. * patient with uncontrolled hypertension and patient with organ damage related to hypertension such as left ventricular hypertrophy or grade 2 ocular fundoscopic changes or kidney impairment. * patients with growing vessel disease (eg age-related macular degeneration, diabetic retinopathy, rheumatoid arthritis), or ongoing wound healing process. patients should be enrolled in the study at least 28 days after surgery. * 12-lead electrocardiogram: st- and t-wave changes suggesting ischemia * hypertension defined as systolic blood pressure (bp)\>140 mmhg or diastolic bp\>90 mmhg on two repeated measurements at 30 minutes intervals. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.